` TSHA (Taysha Gene Therapies Inc) vs S&P 500 Comparison - Alpha Spread

TSHA
vs
S&P 500

Over the past 12 months, TSHA has outperformed S&P 500, delivering a return of +18% compared to the S&P 500's +13% growth.

Stocks Performance
TSHA vs S&P 500

Loading
TSHA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TSHA vs S&P 500

Loading
TSHA
S&P 500
Difference
www.alphaspread.com

Performance By Year
TSHA vs S&P 500

Loading
TSHA
S&P 500
Add Stock

Competitors Performance
Taysha Gene Therapies Inc vs Peers

S&P 500
TSHA
ABBV
AMGN
GILD
VRTX
Add Stock

Taysha Gene Therapies Inc
Glance View

Market Cap
647.4m USD
Industry
Biotechnology

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

TSHA Intrinsic Value
0.71 USD
Overvaluation 72%
Intrinsic Value
Price
Back to Top